16:24 EDT Evolus (EOLS) down 25% at $6.66 after Q2 earnings miss
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus, Inc. Advances NUCEIVA Safety Study: Key Insights for Investors
- Evolus launches Nuceiva neurotoxin in France through Symatese partnership
- Evolus: Strategic Positioning and Growth Potential Drive Buy Rating
- Closing Bell Movers: Gitlab down 13%, Dave & Busters up 10% post earnings
- Evolus director buys $189K in common stock